Compare THRY & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | THRY | FHTX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.6M | 173.4M |
| IPO Year | 2020 | 2020 |
| Metric | THRY | FHTX |
|---|---|---|
| Price | $1.25 | $1.85 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 10 |
| Target Price | $4.00 | ★ $4.17 |
| AVG Volume (30 Days) | 591.9K | ★ 1.1M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.50 | 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $785,015,000.00 | $30,909,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $1.26 | $1.79 |
| 52 Week High | $12.57 | $7.61 |
| Indicator | THRY | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 24.34 | 14.88 |
| Support Level | N/A | $1.79 |
| Resistance Level | $2.17 | $5.35 |
| Average True Range (ATR) | 0.09 | 0.25 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 0.00 | 1.04 |
Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable small and medium-sized business clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation. The group has two business segments; Thryv SaaS deriving maximum revenue and Thryv Marketing Services.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.